GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Invuity Inc (NAS:IVTY) » Definitions » Debt-to-EBITDA

Invuity (Invuity) Debt-to-EBITDA : -1.12 (As of Jun. 2018)


View and export this data going back to 2015. Start your Free Trial

What is Invuity Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Invuity's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2018 was $10.03 Mil. Invuity's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2018 was $24.63 Mil. Invuity's annualized EBITDA for the quarter that ended in Jun. 2018 was $-31.09 Mil. Invuity's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2018 was -1.11.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Invuity's Debt-to-EBITDA or its related term are showing as below:

IVTY's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.225
* Ranked among companies with meaningful Debt-to-EBITDA only.

Invuity Debt-to-EBITDA Historical Data

The historical data trend for Invuity's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invuity Debt-to-EBITDA Chart

Invuity Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17
Debt-to-EBITDA
-0.21 -0.49 -0.43 -0.40 -0.98

Invuity Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.61 -1.10 -1.43 -0.83 -1.12

Competitive Comparison of Invuity's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Invuity's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invuity's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Invuity's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Invuity's Debt-to-EBITDA falls into.



Invuity Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Invuity's Debt-to-EBITDA for the fiscal year that ended in Dec. 2017 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.859 + 29.116) / -35.556
=-0.98

Invuity's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2018 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10.026 + 24.632) / -31.092
=-1.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2018) EBITDA data.


Invuity  (NAS:IVTY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Invuity Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Invuity's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Invuity (Invuity) Business Description

Traded in Other Exchanges
N/A
Address
Invuity Inc is a United States-based commercial-stage medical technology company which utilizes its proprietary Intelligent Photonics technology to develop single-use and reusable illuminated surgical devices. It provides surgeons with illumination and direct visualization of surgical cavities during open minimally invasive and minimal access procedures. Its products include Eikon Illuminated Retractor System, Saber Yankauer, Saber Frazier, Eika Illuminated Retractor System, Breiten Illuminated Retractor System, Eipex Illuminated Retractor System, Eivector Illuminated Retractor System, Waveguide XT System, among others. It sells directly to hospitals, surgeons typically drive the purchasing decision.
Executives
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Eric W Roberts director VALENCE LIFE SCIENCES LLC, 500 PARK AVENUE 9TH FLOOR, NEW YORK NY 10022
William W Burke director 3868 MOCKINGBIRD LN, DALLAS TX 75205
Randall A Lipps director 1101 EAST MEADOW DR, PALO ALTO CA 94303
Dan Wolterman director 3721 VALLEY CENTRE DR, SUITE 500, SAN DIEGO CA 92130
James H Mackaness officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Reza Zadno director 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas A Pepper 10 percent owner C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Philip T Gianos 10 percent owner 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Keval Desai 10 percent owner 467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022
Interwest Partners X Lp 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022